Meso Developing Active

Resurgimiento de biotech: actividad de M&A y rendimiento del mercado

Puntuación
0,4
Velocidad
▲ 0,0
Artículos
13
Fuentes
2

Resumen

Un artículo pertenece a esta narrativa si discute el resurgimiento de los mercados de biotecnología, centrándose en la actividad de fusiones y adquisiciones (M&A) y el rendimiento general del mercado.

Artículos Relacionados

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

Yahoo Finance · Mar 21, 2026
Mixed

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year

Nasdaq · Mar 20, 2026
Mixed

My Top 3 Drug Stocks for March 2026

Nasdaq · Mar 20, 2026
Bearish

Why biotech is back: IBT portfolio manager’s view

Yahoo Finance · Mar 20, 2026
Mixed

Fuentes

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI’s … Yahoo Finance
2 Healthcare Stocks That Could Soar Over the Next 5 … Nasdaq
Moderna Stock is Soaring. Is It Too Late to Buy? Nasdaq
Two Biotech Stocks Hover Near Highs; Natural Gas And Finance … Yahoo Finance
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but … Nasdaq
This Biotech Was Quietly Bought Before a $58 Per Share … Yahoo Finance
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, … Yahoo Finance
This $91 Million Position Signals Conviction in a Biotech Stock … Nasdaq
My Top 3 Drug Stocks for March 2026 Nasdaq
2 Healthcare Stocks to Buy Before They Get Bought Out Nasdaq
Why biotech is back: IBT portfolio manager’s view Yahoo Finance

Cronología

Última actualización Mar 20, 2026